Drug Trial Shows That The Risk Of ER-positive Breast Cancer Can Be Cut By 39 Per Cent

Wed, 21 Feb 2007 05:00 AM EST

... Results from a 20-year trial at the Royal Marsden have today revealed that tamoxifen, a drug that blocks oestrogen, reduces the risk of women developing ER-positive breast cancer by 39 per cent. This finding emerged in the second decade of the long-running Royal Marsden cancer prevention study which involved 2,471 healthy women at high risk of developing breast cancer. [click link for full article] ...